- Peptide Substrates
- Binding Proteins
- Secondary Antibodies
- Regulatory proteins
- 脂类激酶
- 双加氧酶与蛋白质
- 脂质底物
- E2
- Assay Buffer and Co-factors
- Methyltransferases
- Acetyltransferases
- Transcription Proteins
- COVID-19 ELISA Kits
- Tau Proteins
- Microtubule & Actin Associated Proteins
- Carbohydrate Substrates
- COVID-19 Proteins
- Chemokines
- 标记抗体
- 授予称号
- E3
Overview:
MDM4 is a nuclear protein that contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus. MDM4 shows structural similarity to p53-binding protein MDM2 and both proteins bind the p53 tumor suppressor protein and inhibit its activity. However, unlike MDM2, MDM4 does not cause nuclear export or degradation of p53. Instead, MDM4 inhibits p53 activity by binding to the transcriptional activation domain of p53. MDM4 is overexpressed in a variety of human cancers (1). Expression level of MDM4 is significantly higher in chronic lymphocytic leukemia. MDM4 is a specific chemotherapeutic target for treating retinoblastoma (2).
Gene Aliases:
DKFZp781B1423; HDMX; MDMX; MGC132766; MRP1
Genbank Number:
NM_002393
References:
1. Parant, J.et.al: Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 29: 92-95, 2001.2. Laurie, N. A. et.al: Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66, 2006.